A combination of three drugs, elexacaftor/tezacaftor/ivacaftor (ETI) , has been shown to improve lung function and reduce pulmonary exacerbations in cystic fibrosis (CF) patients. 1 However, the impact of ETI on sputum viscoelastic properties, airway infection, and inflammation is unknown. A study examined whether ETI therapy can improve the viscoelastic properties of sputum and reduce these complications in CF patients aged 12 years and above. 2 In the 12-month study, ETI improved the patients' sputum viscoelastic properties at months 3 and 12.
In addition, ETI reduced the abundance of Pseudomonas aeruginosa in sputum at 3 months and improved the microbiome ฮฑ-diversity throughout the study period. Furthermore, ETI significantly decreased interleukin-8 at 3 months and free neutrophil elastase activity in the sputum throughout the study duration. This study reported that the effects ofโฆ
